Abstract
Sarcopenia is defined as a geriatric syndrome based on a generalised skeletal muscle loss and impairment of physical performance. Sarcopenia is associated with an increased likelihood of adverse outcomes including falls, fractures, disability and mortality. Since October 2016 there is an ICD-10-CM code (M62.84) for sarcopenia in the USA. In Germany (ICD-10-GM) it is possible to encode sarcopenia since 2018 (M62.50). For screening in the primary care setting, a questionnaire (SARC-F) has been introduced to identify patients at risk for sarcopenia, leading to further diagnostics. According to the current revised version of the European sarcopenia consensus definition, therapy and further assessment of causes can already be started when reduced muscle strength is diagnosed. At present, the therapy consists of resistance and balance training as well as nutritional advice with the aim of a protein-rich diet. A drug treatment of sarcopenia is not available so far. However, some substances are in clinical trials. Most promising seems to be the group of myostatin antagonists.
Dokumententyp: | Zeitschriftenartikel |
---|---|
Fakultät: | Medizin |
Themengebiete: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit |
ISSN: | 1019-1291 |
Sprache: | Deutsch |
Dokumenten ID: | 86257 |
Datum der Veröffentlichung auf Open Access LMU: | 25. Jan. 2022, 09:18 |
Letzte Änderungen: | 25. Jan. 2022, 09:18 |